Here are 1-3 brief analogies for Adicet Bio:

• It's like a Gilead or Novartis, but focused on next-generation 'off-the-shelf' cell therapies for cancer.

• Think of it as the Moderna of gamma delta T cell therapies for cancer.

• It's like a Kite Pharma for 'off-the-shelf' gamma delta T cell cancer treatments.

• ADI-001: This is an allogeneic gamma delta T cell therapy currently in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
• ADI-002: This is an allogeneic gamma delta T cell therapy undergoing preclinical studies for the treatment of various solid tumors.

Adicet Bio (ACET) is a biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies. Its lead product, ADI-001, is currently in Phase I clinical study for non-Hodgkin's lymphoma, and ADI-002 is in preclinical studies.

As a clinical-stage biotechnology company, Adicet Bio does not currently have major customers in the traditional sense, as its products are still in development and not yet approved for commercial sale. Companies at this stage primarily focus on research, development, and clinical trials. Their funding typically comes from investors, and potential future revenue streams would involve licensing agreements or commercial sales to hospitals, clinics, or pharmaceutical distributors once a product gains regulatory approval.

Chen Schor, President and Chief Executive Officer

Chen Schor has served as President and CEO of Adicet Bio since September 2020. With over 25 years of global biopharmaceutical leadership experience, he has guided several biotech companies through various stages, from formation to publicly traded multi-product companies with significant industry partnerships. Mr. Schor has overseen strategic transactions exceeding $8 billion with companies such as GSK, Amgen, Pfizer, and Merck KGaA, and has led equity financing totaling over $500 million. He was a Partner at Yozma Venture Capital, where he was instrumental in founding and growing multiple therapeutic companies to commercial success and exit. He also served as President, CEO, CFO, Secretary, and Director of resTORbio, Inc., which he founded in 2016, and Adicet's public company operations began after a reverse merger with resTORbio in September 2020. His past executive roles include President, CEO, and Director at Synta Pharmaceuticals Corp., Novalere, Inc., and Adicet Therapeutics, Inc.

Nick Harvey, Chief Financial Officer

Nick Harvey has been the Chief Financial Officer for Adicet Bio since September 2020. He possesses over 20 years of experience in building and financing life science and technology businesses. Before joining Adicet, Mr. Harvey served as the Executive Vice President and Chief Financial Officer of Centrexion Therapeutics, a privately held biotechnology company. Prior to that, he was the Chief Financial Officer of Radius Health for over ten years, where he played a key role in the company's successful initial public offering in 2014 and its transition from a research and development stage to a commercial organization. He also previously held a position as Managing Director at Shiprock Capital, a venture capital firm, where he managed investments and the development of early and late-stage companies.

Blake Aftab, Ph.D., Chief Scientific Officer

Dr. Blake Aftab joined Adicet Bio in April 2021. He brings nearly 20 years of extensive experience from academia, biotech, and pharmaceutical industries, specializing in the development of various therapeutic modalities including small molecules, biologics, antibody-drug conjugates, and cell therapies across all stages of drug development. Prior to Adicet, Dr. Aftab was Vice President and Head of Preclinical Science and Translational Medicine at Atara Biotherapeutics, Inc., a publicly traded immunotherapy company, where he contributed to the company's shift to cell therapy and spearheaded the development of Allo-CAR T cell capabilities.

Julie Maltzman, M.D., Chief Medical Officer

Dr. Julie Maltzman was appointed Chief Medical Officer of Adicet Bio, effective January 13, 2025, succeeding Francesco Galimi. She has over 20 years of broad experience leading clinical development efforts in both oncology and autoimmune diseases, spanning all phases of drug development from early-stage research to global regulatory filings, approvals, and commercialization. Before Adicet, Dr. Maltzman served as Chief Medical Officer at IconOVir Bio. Her previous experience includes serving as VP, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech, where she oversaw the global registration and commercialization of the solid tumor combination therapy Tecentriq+Avastin and co-led the cross-functional team for all Tecentriq program activities. She also held leadership roles at Gilead and GlaxoSmithKline (GSK).

Donald Healey, Ph.D., Chief Technology Officer

Dr. Donald Healey joined Adicet Bio in October 2020 as Chief Technology Officer. He contributes nearly two decades of experience in cell therapy development and manufacturing to the company.

The key risks for Adicet Bio (ACET) primarily stem from its status as a clinical-stage biotechnology company developing cell therapies for cancer and autoimmune diseases.

1. Clinical Trial and Regulatory Approval Risk: Adicet Bio's success is highly dependent on the outcomes of its clinical trials, particularly for its lead product candidate, prula-cel (formerly ADI-001), which is in Phase I studies for non-Hodgkin's lymphoma and autoimmune diseases. There is inherent uncertainty in clinical trials, with high attrition rates and the possibility that product candidates may fail to demonstrate adequate safety or efficacy. Adverse results or delays in these trials could significantly impede or prevent regulatory approval and commercialization, severely impacting the company's business prospects and financial condition.
2. Need for Additional Financing: As a clinical-stage company, Adicet Bio currently generates no revenue and incurs substantial research and development expenses. The company is "quickly burning through cash" and will require significant additional capital to advance its product candidates through further clinical development and eventual commercialization. Although Adicet Bio reported a cash position of $158.5 million as of December 31, 2025, expected to fund operations into the latter part of 2027, extended trial timelines or unforeseen expenses could necessitate earlier fundraising, potentially leading to shareholder dilution or increased debt burden. The company's probability of bankruptcy is estimated at 49.5%.
3. Intense Competition: The field of cell therapies for cancer and autoimmune diseases is highly competitive and rapidly evolving. Adicet Bio's focus on allogeneic gamma delta T cell therapies offers a differentiated approach, but it faces competition from numerous larger pharmaceutical companies and other biotechnology firms with greater financial resources, more established market presence, and potentially more advanced development or commercialization efforts. This competitive landscape could make it challenging for Adicet Bio to gain market share or secure intellectual property advantages.

Adicet Bio, Inc. (NASDAQ: ACET) is a biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company's main product candidates in its pipeline are ADI-001, which targets non-Hodgkin's lymphoma, and ADI-212 (previously ADI-002/ADI-270), which is in preclinical development for solid tumors, specifically metastatic castration-resistant prostate cancer (mCRPC).

ADI-001 (Non-Hodgkin's Lymphoma)

The global addressable market for non-Hodgkin's lymphoma (NHL) therapeutics is substantial and projected to grow. In 2025, the global non-Hodgkin lymphoma therapeutics market size was valued at approximately USD 10.99 billion and is predicted to increase to about USD 20.94 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 7.43% from 2025 to 2034. Another estimate places the global non-Hodgkin lymphoma therapeutics market at USD 11.59 billion in 2025, with a projection to reach USD 19.44 billion by 2034, growing at a CAGR of 6.25%. North America plays a significant role in this market, holding the largest share, estimated at 43% in 2024. The U.S. non-Hodgkin lymphoma therapeutics market alone recorded USD 3.9 billion in 2023.

ADI-212 (Solid Tumors - Metastatic Castration-Resistant Prostate Cancer)

Adicet Bio's ADI-212 is an investigational candidate designed to target prostate-specific membrane antigen (PSMA) for solid tumors, with an initial focus on metastatic castration-resistant prostate cancer (mCRPC). The broader global solid tumor therapeutics market represents a significant addressable market. It was valued at approximately USD 210.46 billion in 2024 and is projected to reach USD 408.47 billion by 2033, exhibiting a CAGR of 7.70% during the forecast period. Another report estimates the global solid tumor therapeutics market at USD 222.71 billion in 2023, with a projection to reach USD 885.44 billion by 2033, growing at a CAGR of 14.80%. North America held a dominant position in the global solid tumor therapeutics market, accounting for approximately 40.8% of the total market share throughout the forecast period.

Adicet Bio (NASDAQ: ACET) is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies. While currently pre-revenue from product sales, the company's future revenue growth over the next 2-3 years is expected to be driven by significant advancements in its pipeline, particularly its lead product candidates.

Here are 3-5 expected drivers of future revenue growth for Adicet Bio:

1. Advancement of Prula-cel (ADI-001) into Pivotal Trials for Autoimmune Diseases: Adicet Bio is making significant progress with its lead product candidate, prula-cel (formerly ADI-001), in autoimmune diseases such as lupus nephritis (LN) and systemic lupus erythematosus (SLE). The company plans to meet with the FDA in the second quarter of 2026 to discuss pivotal trial design and aims to initiate a pivotal study in LN or LN and SLE patients in the second half of 2026. This progression towards late-stage clinical development and potential regulatory submission is a critical driver for future revenue. Prula-cel has also received Fast Track Designation from the FDA for several autoimmune indications, which could accelerate its development and review.
2. Expansion of Prula-cel (ADI-001) into Additional Autoimmune Indications: Beyond LN and SLE, Adicet is expanding the evaluation of prula-cel into other autoimmune diseases, including systemic sclerosis (SSc) and treatment-refractory rheumatoid arthritis (RA). A Phase 1 study for RA is underway, with data expected in the second half of 2026, broadening the potential market for this lead candidate. Successfully developing prula-cel across multiple indications could substantially increase its market potential and future revenue streams.
3. Initiation of Clinical Development for ADI-212 in Solid Tumors: Adicet Bio is advancing ADI-212, a new solid tumor candidate for metastatic castration-resistant prostate cancer (mCRPC). The company plans to submit a regulatory filing for ADI-212 in the third quarter of 2026, with Phase 1 enrollment projected to begin in the fourth quarter of 2026, pending regulatory clearance. Entry into the large oncology market with this novel gamma delta T cell therapy represents a significant potential revenue driver.
4. Positive Clinical Data Readouts and Regulatory Milestones: The ongoing and anticipated clinical updates for prula-cel in autoimmune diseases throughout 2026, along with the expected initiation of ADI-212's clinical trial, are crucial catalysts. Positive safety and efficacy data, coupled with favorable regulatory interactions (such as the FDA alignment for outpatient dosing of prula-cel), will de-risk the programs and pave the way for accelerated development, eventual regulatory approval, and commercialization, thereby driving future product revenue.

Share Issuance

• In October 2025, Adicet Bio completed an underwritten registered direct offering, generating approximately $74.8 million in net proceeds.
• The company also secured approximately $152 million in gross proceeds from a public offering of common stock and a concurrent private placement.
• In December 2025, Adicet Bio effected a one-for-16 reverse stock split to reduce its outstanding shares from approximately 153.3 million to around 9.6 million, primarily to regain compliance with Nasdaq's minimum bid price requirement.

Inbound Investments

• Adicet Bio’s revenue to date has been derived from collaboration arrangements rather than product sales.

Capital Expenditures

• In Q3 2025, Adicet Bio reported $209K in capital expenditures.
• The company completed plant automation upgrades and expanded fulfillment capacity as operational milestones.